

Preparing Your Audit Response: Corrective Action Plans (CAP)

Barbara Barrett, Audit Program Manager

Alliance Chicago Office

Alliance Summer 2012 Group Meeting

Audit Exit Interview

- Take notes throughout audit and at Exit Interview
- Make sure to understand the comments from the Exit Interview, don't be afraid to ask questions



Preparing the Audit Report

- Team Leader creates a draft audit report and resolves any outstanding issues with the site.
- A second review is conducted to check for accuracy and for consistency between sites.



The Final Report

The final version is submitted in the CTMB via the AIS (Audit Information System) electronic database.

The final audit report is sent via electronic mail and/or Fed Ex to the Principal Investigator and Lead CRA



Audit Report Distribution

It is the Main Member's responsibility to review the audit report with affiliate(s)/components.

Communication between main member and affiliate is key.



Understanding the Audit Report

Reminder of three audit components:

- IRB/ Consent Content
- Pharmacy
- Patient Case Review



Understanding the Audit Report

Category ratings:

- *OK* (no deficiency is warranted)
- Lesser Deviation (minor deficiency)
- *Major Deviation* (significant error or omission)



Understanding the Audit Report

Overall Category Assessment:

<u>Acceptable</u> – No follow-up is needed

<u>Acceptable Needs Follow-up</u> – corrective action plan required within 15 business days

<u>Unacceptable</u> – As above and re-audit scheduled within 12 months required



Clinical Trials Monitoring Branch - Final Report


Due Dr. CUEDEDC						Date: 1/26/200	07
Run By : SCHERERS						Page:	1 of 10
udit Date : Institution Code : Main Member / CCOP Code : Audit Location :	12/01/2006 CK000 CO000	Group : C/ Name : Name :	ALGB Audit Category :	Treatment	Audit Type :	Routine audit	
	0	Revision	n Date: 0 1-DEC-06				
Date of Prior Audit :	Number	of Cases Audited :10	Average Annual Accrual :10	Principal	Investigator :	Tom Jones, MD	
Audit Outcome Summary							
Component			F	ollowup Required (Y/N)	Followup Du	Reaudit Required e (Y/N)	Reaudit Tim (in months)
RB and Informed Consent Conter	nt Review		Acceptable needs follow-up	Yes	02/23/2007	No	
ccountability of Investigational	Agents and Pharm	nacy Operations Review	Acceptable needs follow-up	Yes	02/27/2007	No	
Patient Case Review			Unacceptable	Yes	02/23/2007	Y	18 Months
Reaudit Timeline History							
Component		Readuit Time	Readuit CTMB Comments				
RB Reaudit Time Line History							
harmacy Reaudit Time Line Histo	ory						
Patient Case Reaudit Time Line Hi	story	18 months					
institution Staff		Title		Affiliation			
Audit Team		Title		Affiliation			
Weiss, Raymond B. (MD)		Team Leader		Georgetown U	niversity Medica	lCenter	
Co-site Visitor		Title		Affiliation			

If you received an IRB Unacceptable rating...

- Alliance policy An Unacceptable rating in any section of the audit is evaluated on a case-bycase basis and may warrant immediate suspension of registration privileges.
- This suspension will be lifted when a response is submitted and found to be Acceptable.



Sample Audit Reports





Audit Report Cover Letter

- Summarizes the three ratings: *The IRB/Consent Content review was rated Acceptable Needs Follow-up. The deficiency includes..... Pharmacy review was rated Acceptable. The Patient Case review was rated Unacceptable. The deficiencies include......*

- Provide a date the CAP is due: A written corrective plan addressing the deficiencies in these areas must be submitted by **Tuesday, July 19, 2012.**



Clinical Trials Monitoring Branch - Final Report

							Date: 01/2'	7/2007
Run By: SCHERERS							Page:	10 o
Audit Date :	12/01/2006		CALGB	Audit Ca	tegory : Treatmen	t Audit Typ	e: Routine audit	
Institution Code : Main Member / CCOP Code Audit Location :	:	Name : Name :						
Revision Number:	2	Revis	ion Date:	2-J	AN-07			
Protocol #	Patient #	Informed Consent	Eligibility		Treatment	Toxicity	Disease Outcome	Data Quality
CALGB-XXXX	xxxxx	OK		OK	OK	OK	OK	Major
Total # of Major deficiencie	es: 2	Total # c	of Lesser defi	ciencies : 0	Total # of d	leficiencies Not Review	red : 0	
Total # of Patient cases :	1	Total # o	of Patient cas	es: 1				
Patient Case Review Ass	essment							
Patient Case Review A	Assessment :		Acceptable n	eeds follow-up	i .			
Follow-up required for Informed Consent :			No					
Follow-up required for	r Eligibility :		No					
Follow-up required for Treatment :		No						
Follow-up required for Disease Outcome/Response :		No						
Follow-up required for Toxicity :			No					
Follow-up required for General Data Quality :		Yes (COMMENTS :	The required submit Center should now	ssion of the pathology ar be done.	nd operative reports to	the Data Operation:	
Re-audit required :			No					
Audit Procedures : The audit was conducted at the prac			actice offices of the and followed normal C/			ALGB procedures.		
General Comments :	corrected jus	st prior to the audit. He	wever, the sit	e should note t		e were 2 major deficiencie f this one study must con		
Exit Interview Comments :	corrected just prior to the audit. However, the site should note that annual renewals of this one study must continue as long as CALGB is collecting data for this one patient. One major deficiency in the Patient Case review was corrected in preparation for the audit. Another one (the deficiency in submitting the pathology and operative reports) must now be corrected. A written response regarding the above deficiencies must be submitted by An exit interview was held with s, and the deficiencies were discussed.							

Submission of CAPs

CAPS should include:

- measures for prevention of deficiencies in the future, e.g. revision of your P&Ps, additional training, discussion with IRB regarding procedures and timelines, re-education of staff involved.
- Confirmation of correction for specific deficiencies, e.g., submission of outstanding data.



Submission of CAPs

- Author(s) of CAP should be identified.
- CAP MUST be submitted on letterhead and signed by the PI plus any other author.
- Attach any needed support documentation.
- No need to attach copy of your audit report.
- Submit CAPs via email or fax, following up with originals.



CAP Review

- The audit program manager (APM) reviews the corrective action plan to determine if the response is Acceptable. If the CAP is not Acceptable, clarification of additional information will be requested. (*happy to review drafts!*)
- The APM will submit the CAP to CTMB.
- If the CTMB requires additional information, they will contact the group. We do not receive notification of acceptance of CAPs from CTMB.



Writing a Satisfactory CAP

- Address each issue listed in report as needing follow-up.
- Address 3 questions:
 - Why did this deficiency occur? (i.e, what was the problem?)
 - Has the specific problem been corrected (*i.e.* has the outstanding data in question been submitted? Has the patient been re-consented with the updated consent form?)
 - What plan has been implemented to ensure this type of deficiency will not occur in the future?



Samples of Acceptable/Unacceptable Corrective Action Plans







IRB Deficiency

Major Deficiency	Partially Acceptable CAP
Update #6 posted on 02/15/11 has not been approved by the IRB. Three IND reports posted on 03/15/11 have not been submitted to the IRB.	As updates and safety reports are identified, they will be entered on the Outlook calendar to submit and track.



IRB Consent Content Deficiency

Major Deficiency	Partially Acceptable CAP
The local ICF does not include sample submission question #1 from page 2 of the model consent. This study is still open to new enrollment.	A revision has been submitted to the IRB that includes all model consent questions. The site will now use the consent content checklist and review local consents compared to model consents.



Pharmacy Deficiency

Major Deficiency	Acceptable or
	Unacceptable Plan?
Patient returned drug was logged back onto the DARF for this open labeled study.	Two new sections have been added to our Pharmacy policy (see attached). One is "Patient Return of Unused Study Medication" and the other is to include the CTMB Guidelines section 5.3. Pharmacy staff have been re-educated.



Treatment Deficiency

Major Deficiency	Acceptable or Unacceptable Plan?
Dose modification error for Cycle 4. A 25% dose was warranted and the patient received a 40% dose reduction. This is greater than 10% margin of error.	"In reviewing these, I believe she did a very good job overall, but there were some confusing items which were misinterpreted. I believe that with her experience now, the next case would be much better."



Data Quality Deficiency

Major Deficiency	Acceptable or Unacceptable Plan?
Per the Pathology Coordinating Office, the study required blood samples and blocks were not submitted.	"This was an isolated event and we do not feel it will occur again."



Data Quality Deficiency

Major Deficiency	Acceptable or Unacceptable Plan?
Data forms for treatment, AE and disease response have not been submitted since cycle #7 (11/19/10). Patient had progressive disease on 11/26/2011.	All forms have been submitted. The cancer center has hired an additional experienced CRA. Next monthly staff meeting will cover data submission schedules. A quarterly review of data will be performed by the office manager."



Two Consecutive Unacceptable Ratings? (In the same component)

CTMB section 6.3.2: Probation of Participating Institutions

- The institution will be placed on probation.
- The Group may assign a mentor.
- A "site improvement plan" must be developed to "address key infrastructural issues contributing to poor performance" (ALL this in addition to the corrective plan.)



Example: Site Improvement Plan for IRB

- The local IRB policies were revised in response to the audit findings.
- The main member network will cover the costs of the site's CRA to attend the audit prep workshop at the next Alliance group meeting.
- The Lead CRA will perform two IRB audits of the affiliate over the next year.



Audit Program Managers:

- Tammy Neseth
 - <u>neseth.tammy@mayo.edu</u>
 - Phone: (507) 266-4051
 - Fax: (507) 284-2643
- Jean Wittlief
 - <u>e.wittlief@duke.edu</u>
 - Phone: 919-602-8735
 - Fax: 919-266-5195

- Barbara Barrett
 - <u>bbarrett@uchicago.edu</u>
 - Phone: (312) 206-8216
 - Fax: (312) 345-0117



Additional Contact Information

- Crystal Newkirk, Audit Coordinator
 - cnewkirk@uchicago.edu
 - Phone: (773) 702-9973
 - Fax: (312) 345-0117
- Dawn Deno, Audit Coordinator
 - <u>Deno.dawn@mayo.edu</u>
 - Phone: 507-284-8755
 - Fax: Fax: (507) 284-2643



Thank you!





